Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lixivaptan - Palladio Biosciences

Drug Profile

Lixivaptan - Palladio Biosciences

Alternative Names: CRTX 080; Lixar; VPA 985; WAY VPA 985

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Chiesi USA; Palladio Biosciences
  • Class Azepines; Benzamides; Small molecules; Urologics
  • Mechanism of Action Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autosomal dominant polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autosomal dominant polycystic kidney disease
  • Preclinical Autosomal recessive polycystic kidney disease; Kidney disorders
  • Discontinued Hyponatraemia

Most Recent Events

  • 08 Nov 2019 Palladio Biosciences plans a phase III trial for Autosomal dominant Polycystic kidney disease in February 2020 (PO) (NCT04152837)
  • 06 Nov 2019 Preliminary pharmacodynamic and adverse events data from the phase II ELISA trial in Autosomal dominant polycystic kidney disease released by Palladio Biosciences
  • 22 Aug 2019 Palladio Biosciences plans a phase III trial for Autosomal dominant polycystic kidney disease (PO) in March 2020 (NCT04064346)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top